■评估局部皮质类固醇(TCS)在预防乳腺癌患者急性放射性皮炎中的作用。
■在系统评价和荟萃分析的首选报告项目之后,进行了更新的系统评价和荟萃分析。六个英文数据库中的随机对照试验(RCT)(PubMed,WebofScience,Scopus,CINAHL,科克伦图书馆,Embase),三个中文数据库(Sinomed,中国国家知识基础设施,Cqvip),和两个临床试验注册平台(CHICTR,Clinicaltrials.gov)从开始到2024年2月1日进行了系统搜索。
■包括13个RCT,在这篇更新的综述中,有1172名患者。Meta分析显示,TCS降低了湿脱皮率(OR=0.31;95%CI=[0.22,0.44];P<0.01),肿瘤放射治疗组的发病率为2级或更高(OR=0.22;95%CI=[0.14,0.32];P<0.01),2级或以上不良事件常用术语标准的发生率(OR=0.56;95%CI=[0.37,0.84];P<0.01),放射性皮炎的平均评分(SMD=-0.46;95%CI=[-0.59,-0.34];P<0.01),皮肤红斑和色素沉着过度,改善主观症状。
■TCS可有效预防乳腺癌患者的急性放射性皮炎。
■Prospero(CRD42024507890)。
UNASSIGNED: To evaluate the effect of topical corticosteroids (TCS) in preventing acute radiation dermatitis in patients with breast cancer.
UNASSIGNED: An updated systematic review and meta-analysis were conducted following the preferred reporting items for systematic reviews and meta-analyses. Randomized controlled trials (RCTs) in six English databases (PubMed, Web of Science, Scopus, CINAHL, Cochrane Library, Embase), three Chinese databases (Sinomed, China National Knowledge Infrastructure, Cqvip), and two clinical trial registration platforms (CHICTR, Clinicaltrials.gov) were systematically searched from inception to 1 February 2024.
UNASSIGNED: Thirteen RCTs were included, with 1172 patients in this updated review. Meta-analysis showed that TCS reduced the rate of moist desquamation (OR = 0.31; 95% CI = [0.22, 0.44]; P < 0.01), the incidence of Radiation Therapy Oncology Group ratings of grade 2 or higher (OR = 0.22; 95% CI = [0.14, 0.32]; P < 0.01), the incidence of Common Terminology Criteria for Adverse Events ratings of grade 2 or higher (OR = 0.56; 95% CI = [0.37, 0.84]; P < 0.01), the mean score of radiation dermatitis (SMD = -0.46; 95% CI = [-0.59, -0.34]; P < 0.01), skin erythema and hyperpigmentation readings, and improved subjective symptoms.
UNASSIGNED: TCS can effectively prevent acute radiation dermatitis in patients with breast cancer.
UNASSIGNED: Prospero (CRD42024507890).